Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "2025年12月29日至2026年1月2日603290股价走势预测"

Looking for quality documents?
news icon
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
external link icon
Repligen to Report Third Quarter 2018 Financial Results
- Webcast and Conference Call to Be Held Thursday, November 1, 2018 at 8:30 a.m. EDT - WALTHAM, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter of 2018 financial results on Thursday, November 1, 2018. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine-month reporting periods ended September 30, 2018. 

The conference call will be accessible by dialing toll-free (866) 777-2509 for domestic callers and (412) 317-5413 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the
external link icon
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign’s machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest in Novasign to help scale and expand operations. Through this collaboration, Novasign’s unique modeling workflow will be integrated into Repligen’s tangential flow filtration (TFF) systems. This will not only enhance Repligen’s digitalization journey and strengthen its portfolio of process analytical technology (PAT)-enabled systems but also unlock the potential for future advanced AI modeling within Repligen platforms. The end goal is to streamline process development, enable real-time predictive control, and significantly reduce development timelines and costs through the deployment of digital
external link icon
Repligen to Report First Quarter 2024 Financial Results
Webcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2024 financial results on Wednesday, May 1, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2024.
The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in
publications icon
Continuous Bioprocessing: Current Practice And Future Potential Publication
E-book Volume 1 2014 Compiled by John Bonham-Carter, Repligen Chapters Introduction to Continuous Manufacturing:Technology Landscape and Trends Eric S. Langer and Ronald A. Rader, BioPlan Associates A Brief History of Perfusion Biomanufacturing Jerry Shevitz and John Bonham-Carter, Refine Technology Bioreactor Configuration and Operation Christel Fenge, Jörg Weyand, Gerhard Greller, Thorsten Adams, Sartorius Stedim Biotech How to Develop a Perfusion Process Véronique Chotteau, Royal Technical University, KTH Case Study: Optimized Perfusion Shaun Eckerle, Gallus BioPharmaceuticals Process Intensification Approaches for Cost Sensitive Protein Applications Willem Adriaan de Jongh, Expres2ion Biotechnologies Impact of Single-use Technology on Continuous Biorocessing William G. Whitford, Thermo Fisher Scientific Continuous Multicolumn Chromatography Processes Marc Bisschops, Tarpon Biosystems Continuous Processes: Economic Evaluation Andrew Sinclair and Andrew Brown, BioPharm Services Vision: Integrating Upstream and Downstream in a Fully Continuous Facility Tim Johnson, Genzyme
external link icon
Repligen to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
WALTHAM, Mass., May 09, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will present at the Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas on Tuesday, May 16 at 2:20 p.m. Pacific Time.
A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the interconnected phases of the biological drug manufacturing process. Our portfolio includes protein products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and
external link icon
Repligen Acquires Bioprocessing Business of Refine Technology
- Expands Portfolio of Products to Improve Efficiencies in Biologic Drug Manufacturing - - Company Updates 2014 Financial Guidance - - Conference Call and Webcast Today at 9:00 a.m. EDT - WALTHAM, Mass., June 3, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has acquired the business of Refine Technology ("Refine"), including Refine's Alternating Tangential Flow ("ATF") System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process. The acquisition strengthens Repligen's bioprocessing business by adding a profitable and highly complementary product line while expanding the Company's direct sales presence worldwide. Repligen has entered into a definitive agreement effective June 2, 2014 to purchase Refine's business for a combination of $20.5 million in cash and 215,285 shares of Repligen common stock, for total upfront consideration of approximately $24.5 million.
external link icon
Repligen Announces Asset Purchase Agreement With BioMarin for HDACi Portfolio
WALTHAM, Mass., Jan. 21, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has entered into an asset purchase agreement with BioMarin Pharmaceutical Inc. ("BioMarin") to advance Repligen's histone deacetylase inhibitor (HDACi) portfolio. The HDACi portfolio includes multiple orally bioavailable small molecule compounds as well as enabling technologies. Under the terms of the agreement, Repligen will receive an upfront payment of $2 million from BioMarin and it has the potential to receive up to $160 million in future milestone payments for the development, regulatory approval and commercial sale of portfolio compounds included in the agreement. In addition, Repligen is eligible to receive royalties on sales of therapeutic products originating from the HDACi portfolio. Potential applications of the HDACi portfolio include Friedreich's ataxia and other neurological disorders. "The outlicensing of our HDAC portfolio, which includes the Friedreich's ataxia
external link icon
Repligen Announces Agreement to Acquire Chromatography Innovator Tantti
Proposed acquisition adds novel macroporous chromatography base bead technology for downstream bioprocess applications
Accelerates expansion into new modality markets with a unique, scalable purification solution Strongly synergistic with AVIPure ® affinity ligands and OPUS ® pre-packed chromatography columns
WALTHAM, Mass., July 29, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Tantti Laboratory Inc. (“Tantti”) of Taoyuan City, Taiwan. Tantti has developed a unique portfolio of macroporous chromatography beads to optimize the purification of new modalities including viral vectors, viruses, nucleic acids and other large molecule biologics. Tantti’s DuloCore ® technology platform combines the high throughput performance of membranes with the rapid mass transfer of monoliths in a
external link icon
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare conference being held January 8-11 in San Francisco. Tony J. Hunt, Chief Executive Officer, will present an overview of the company on Tuesday, January 9, 2024, at 2:15 p.m. PST. A live webcast of the presentation will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen Corporation is a life sciences tools and technology company that develops and markets highly innovative bioprocessing solutions and systems. Our products enable efficiencies in the process of manufacturing a wide range of biological drugs, including: monoclonal antibodies; recombinant proteins; cell and gene therapies; and
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support